Tricuspid Regurgitation: A Clinical Case-based Review of the Cardioband™ Tricuspid Valve Reconstruction System

Tricuspid regurgitation (TR) is largely undertreated, despite its association with significant morbidity and mortality. Isolated tricuspid surgery is generally not recommended due to high risks, especially for those patients with comorbidities. Instead, individuals with severe TR are typically managed medically - however, many patients continue to experience debilitating symptoms. The Edwards Cardioband™ tricuspid valve reconstruction system is a transvenous system to treat TR. It is the first commercially available transcatheter therapy specifically developed for the treatment of TR. Initial results are promising, with positive outcomes in terms of safety, technical success and quality of life improvements. Thus, the Cardioband Tricuspid System could provide a new treatment option for TR.